KR20210014109A - 질환의 예후와 관리 방법 - Google Patents

질환의 예후와 관리 방법 Download PDF

Info

Publication number
KR20210014109A
KR20210014109A KR1020207034330A KR20207034330A KR20210014109A KR 20210014109 A KR20210014109 A KR 20210014109A KR 1020207034330 A KR1020207034330 A KR 1020207034330A KR 20207034330 A KR20207034330 A KR 20207034330A KR 20210014109 A KR20210014109 A KR 20210014109A
Authority
KR
South Korea
Prior art keywords
als
subject
scd14
biomarker
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207034330A
Other languages
English (en)
Korean (ko)
Inventor
스탠리 에이치 어펠
데이비드 알 비어스
Original Assignee
더 메서디스트 하스피틀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 메서디스트 하스피틀 filed Critical 더 메서디스트 하스피틀
Publication of KR20210014109A publication Critical patent/KR20210014109A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
KR1020207034330A 2018-05-10 2019-05-10 질환의 예후와 관리 방법 Ceased KR20210014109A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669915P 2018-05-10 2018-05-10
US62/669,915 2018-05-10
PCT/US2019/031858 WO2019217916A1 (en) 2018-05-10 2019-05-10 Methods for prognosis and management of disease

Publications (1)

Publication Number Publication Date
KR20210014109A true KR20210014109A (ko) 2021-02-08

Family

ID=66655475

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207034330A Ceased KR20210014109A (ko) 2018-05-10 2019-05-10 질환의 예후와 관리 방법

Country Status (8)

Country Link
US (1) US20210231686A1 (https=)
EP (1) EP3791188A1 (https=)
JP (2) JP7371019B2 (https=)
KR (1) KR20210014109A (https=)
CN (1) CN112424608A (https=)
AU (1) AU2019264996A1 (https=)
IL (1) IL278616B2 (https=)
WO (1) WO2019217916A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL309046B2 (en) 2017-04-21 2025-03-01 Implicit Bioscience Ltd CD14 antagonist antibodies for the treatment of neurodegenerative diseases
CN113842449B (zh) * 2021-09-08 2024-02-23 乐卫东 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用
WO2025049671A1 (en) * 2023-08-30 2025-03-06 The Methodist Hospital Markers of amyotrophic lateral sclerosis survival and uses thereof
WO2025058005A1 (ja) * 2023-09-15 2025-03-20 国立大学法人徳島大学 筋萎縮性側索硬化症（ａｌｓ）と関連するバイオマーカー

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
ES2083152T3 (es) * 1990-11-30 1996-04-01 Monoclonetics Int Metodos para el diagnostico de dolores cronicos lumbares y cervicales.
US5820858A (en) 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
CA2319828A1 (en) 1998-01-29 1999-08-05 Miller, Samuel High density arrays for proteome analysis and methods and compositions therefor
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
AU2001255436A1 (en) 2000-04-17 2001-10-30 Transtech Pharma Protein expression system arrays and use in biological screening
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
US20050130320A1 (en) 2000-11-09 2005-06-16 George Shaji. T. Method for identifying the proteome of cells using an antibody library microarray
AU2001290315A1 (en) 2000-11-22 2002-06-03 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
US6800453B2 (en) 2001-01-23 2004-10-05 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
WO2003062444A2 (en) 2001-11-13 2003-07-31 Emory University Array systems and methods
JP2005510524A (ja) * 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
AU2003224674A1 (en) 2002-03-11 2003-09-29 Hk Pharmaceuticals, Inc. Compounds and methods for analyzing the proteome
WO2005020784A2 (en) * 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
ES2406266T3 (es) * 2004-05-11 2013-06-06 Mochida Pharmaceutical Co., Ltd. Antígeno CD14 soluble novedoso
WO2010102412A1 (en) * 2009-03-11 2010-09-16 Augurex Life Sciences Corporation Compositions and methods for characterizing arthritic conditions
BR112012002333A2 (pt) * 2009-08-06 2017-07-18 Neuraltus Pharmaceuticals Inc método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito.
US8465727B2 (en) 2009-10-06 2013-06-18 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers for the diagnosis of ALS
EP2501720A2 (en) * 2009-11-18 2012-09-26 Lascco SA Ifn inhibitors in the treatment of motoneuron diseases
WO2011111043A1 (en) * 2010-03-10 2011-09-15 Yeda Research And Development Co. Ltd Cellular blood markers for early diagnosis of als and for als progression
WO2012004276A2 (en) * 2010-07-06 2012-01-12 Fondazione Telethon Multiprotein biomarkers of amyotrophic lateral sclerosis in peripheral blood mononuclear cells, diagnostic methods and kits
US9506923B2 (en) * 2011-08-12 2016-11-29 Lsi Medience Corporation Method of diagnosing surgical site infections
US10184151B2 (en) * 2011-10-11 2019-01-22 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
WO2014102333A1 (en) * 2012-12-28 2014-07-03 Mitsubishi Chemical Medience Corporation Use of scd14 or its fragments or derivatives for risk stratisfaction, diagnosis and prognosis
EP3142674A4 (en) * 2014-05-16 2018-01-17 Neuraltus Pharmaceuticals, Inc. Methods and compositions for treatment of macrophage-related disorders
WO2016083374A1 (en) * 2014-11-25 2016-06-02 F. Hoffmann-La Roche Ag Biomarkers of fast progression of chronic kidney disease
HK1250012A1 (zh) * 2015-04-02 2018-11-23 The Methodist Hospital System 基於多孔硅微粒的癌症疫苗及增强抗肿瘤免疫的方法
US10724095B2 (en) * 2015-12-16 2020-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections
WO2017147378A1 (en) * 2016-02-25 2017-08-31 The Trustees Of Columbia University In The City Of New York Systemic immune activation and biomarkers of nonceliac wheat/gluten sensitivity
IL309046B2 (en) 2017-04-21 2025-03-01 Implicit Bioscience Ltd CD14 antagonist antibodies for the treatment of neurodegenerative diseases
AU2024238511A1 (en) * 2023-03-21 2025-10-02 Coya Therapeutics, Inc. Biomarkers of amyotrophic lateral sclerosis and uses thereof

Also Published As

Publication number Publication date
IL278616B2 (en) 2025-02-01
IL278616A (https=) 2021-01-31
JP2021523375A (ja) 2021-09-02
US20210231686A1 (en) 2021-07-29
JP7371019B2 (ja) 2023-10-30
IL278616B1 (en) 2024-10-01
CN112424608A (zh) 2021-02-26
EP3791188A1 (en) 2021-03-17
WO2019217916A1 (en) 2019-11-14
JP2023181255A (ja) 2023-12-21
AU2019264996A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
US10877049B2 (en) Biomarkers for diagnosis and management of neuro-immunological diseases
JP2023181255A (ja) 疾病の予後と管理のための方法
JP6404208B2 (ja) 特発性肺線維症の予後予測、診断および処置の方法
US7449303B2 (en) Use of JAG2 expression in diagnosis of plasma cell disorders
JP6868655B2 (ja) Ｃｄ６結合パートナーの使用およびそれに基づく方法
WO2020056162A1 (en) Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival
Zou et al. Single-cell approaches to investigate B cells and antibodies in autoimmune neurological disorders
US20240150836A1 (en) Methods of predicting and treating immunotherapy toxicity based on immune cell populations
AU2020222262B2 (en) Type I interferon-mediated disorders
US7709215B2 (en) Method for diagnosing and treating acute joint injury
JP2023553247A (ja) がん診断のための組成物および方法
EP2795337B1 (en) Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions
US11761963B2 (en) Biomarker signature for predicting tumor response to anti-CD200 therapy
JP2022526131A (ja) 肝細胞癌診断用バイオマーカーセレブロンと、これに特異的な新規なモノクローナル抗体
CA3250546A1 (en) IL7R MODULATOR ACTIVITY BIOMARKERS
Ostalska-Nowicka et al. SOCS3 and SOCS5 mRNA expressions may predict initial steroid response in nephrotic syndrome children
WO2025195496A1 (en) Immunotherapy for ox40 expressing cancer
CN116710782A (zh) 基于wars及细胞因子浓度的有关感染性炎症疾病的死亡风险的判断方法
Class et al. Patent application title: SCREENING METHODS TO IDENTIFY COMPOUNDS USEFUL IN THE PREVENTION AND/OR TREATMENT OF INFLAMMATORY CONDITIONS Inventors: Reginald Christophe Xavier Brys (Mechelen, BE) Reginald Christophe Xavier Brys (Mechelen, BE) Sonia Dupont (Romainville, FR) Assignees: GALAPAGOS NV

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000